Joint modeling of progression-free survival and overall survival by a Bayesian normal induced copula estimation model
Author:
Affiliation:
1. Eli Lilly and Company; Lilly Corporate Center; Indianapolis IN 46285 U.S.A.
Publisher
Wiley
Subject
Statistics and Probability,Epidemiology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/sim.5487/fullpdf
Reference46 articles.
1. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group;Stone;European Journal of Cancer,2011
2. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer;Miller;The New England Journal of Medicine,2007
3. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer;Miles;Journal of Clinical Oncology,2010
4. Ribbon-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer;Robert;Journal of Clinical Oncology,2011
5. The significance of progression-free survival as a clinical end point in oncology;Axelrod;Drug Benefit Trends,2010
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Joint Model with Random Changepoint for Longitudinal Measures and Semi-competing Risks;2024-06-27
2. Bayesian survival extrapolation for cost-effectiveness analysis: a case study of RELAY for ramucirumab in combination with erlotinib in the treatment of non-small-cell lung cancer;Journal of Medical Economics;2023-11-30
3. Bivariate copula regression models for semi-competing risks;Statistical Methods in Medical Research;2023-08-09
4. Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint;BMC Cancer;2023-02-10
5. Estimating the correlation between semi‐competing risk survival endpoints;Biometrical Journal;2021-10-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3